UK markets close in 3 hours 26 minutes

BioPorto A/S (BIOPOR.CO)

Copenhagen - Copenhagen Real-time price. Currency in DKK
Add to watchlist
1.4980+0.0660 (+4.61%)
As of 01:54PM CEST. Market open.
Full screen
Previous close1.4320
Open1.4280
Bid1.4540 x 0
Ask1.4980 x 0
Day's range1.4000 - 1.4980
52-week range1.0020 - 4.1000
Volume83,571
Avg. volume555,236
Market cap501.351M
Beta (5Y monthly)1.19
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Globe Newswire

    BioPorto to Participate in H.C. Wainwright’s 24th Annual Global Investment Conference

    COPENHAGEN, Denmark and BOSTON, Sept. 08, 2022 (GLOBE NEWSWIRE) -- BioPorto A/S (BioPorto) (CPH:BIOPOR) today announced plans to participate in the H.C. Wainwright 24th Annual Global Investment Conference taking place September 12-14, 2022 in New York City. Following are details for management’s presentation: Date: September 12, 2022 Time: Available On Demand at 7am ET Webcast Link: https://journey.ct.events/view/2785e18a-7a71-4dd6-a735-695045a60f04 Management will also be available for 1x1 meet

  • Globe Newswire

    BioPorto Announces Interim Results for the First Six Months of 2022

    August 17, 2022Announcement no. 13 BioPorto Announces Interim Results for the First Six Months of 2022 COPENHAGEN, DENMARK and BOSTON, MA, USA, August 17, 2022, (GLOBE NEWSWIRE) -- BioPorto A/S (BioPorto) (CPH:BIOPOR) today announced interim financial results for the first six months of 2022 and business progress for the second quarter of 2022. Recent Highlights For the six months ending June 30, 2022: Total revenue of DKK 15.0 million / USD 2.2 million, a 23% increase over the prior yearAdjuste

  • Globe Newswire

    BioPorto A/S to Host Quarterly Earnings Webcast and Analyst Call

    August 8, 2022News release BioPorto A/S to Host Quarterly Earnings Webcast and Analyst Call COPENHAGEN, DENMARK and BOSTON, MA, USA, August 8, 2022, (GLOBE NEWSWIRE) -- BioPorto A/S BioPorto A/S (BioPorto) (CPH:BIOPOR), an in vitro diagnostics company focused on empowering the early detection of kidney injury, announced today that in connection with the release of its Interim Report for the second quarter of 2022, the Company’s management team will host an online investor presentation on August